Earnings Preview: SPRY to Report Financial Results Pre-market on May 14
Express News | ARS Pharmaceuticals Inc: Cash Price for Neffy Is $199 for Two Doses on GoodRx Website
ARS Pharmaceuticals' Neffy (Epinephrine Nasal Spray) 1 Mg Is Now Available in the United States for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
ARS Pharmaceuticals And 2 Other Growth Leaders With Insider Ownership
ARS Pharmaceuticals Announces Conference Call and Webcast for Its First Quarter 2025 Financial Results
ARS Pharmaceuticals (SPRY) Gets a Buy From Scotiabank
William Blair Reaffirms Their Buy Rating on ARS Pharmaceuticals (SPRY)
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Stryker (SYK)
ARS Pharmaceuticals Air Lease ALK-Abello
Express News | ARS Pharmaceuticals Inc - Pharma Received $145 Million Upfront From Alk
ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of Neffy (Epinephrine Nasal Spray) to Additional U.S. Pediatricians
Express News | ARS Pharmaceuticals Announces Co-Promotion Agreement With Partner and Global Allergy Leader Alk-Abelló A/S to Expand Reach of Neffy® (Epinephrine Nasal Spray) to Additional U.S. Pediatricians
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $32
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
ARS Pharmaceuticals: Strategic Growth and Market Penetration Justify Buy Rating
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $32
Scotiabank Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals' Earnings Call Highlights Growth and Challenges
Insider Sale: Chief Commercial Officer of $SPRY Sells 10,000 Shares